当前位置:主页 > 医学论文 > 内分泌论文 >

以PTP1B和ALR2为靶点的抑制剂筛选

发布时间:2019-02-13 00:41
【摘要】:糖尿病已经成为了致死率排名世界前5的疾病。近年来DM发病的人数逐年增加,,而且发病年龄有不断降低的趋势,DM和DCC已经成为影响人类生活质量的严重疾病。但现有的药物大都有明显的剂量依赖性或者令人难以接受的副作用,故而寻找合适的药物来治疗这一疾病已经成为现阶段药物开发的重中之重。本文以糖尿病及其并发症的靶点PTP1B和ALR2展开研究。 我们使用PET-30a载体构建了人源ALR2质粒,并于BL21(DE3)大肠杆菌中进行了表达。使用离子交换和活力跟踪的方法进行纯化,得到了相对较纯的人源ALR2蛋白。酶学性质表明,当底物为DL-甘油醛时,最适温度为37℃,最适反应时间为15min,最适反应pH为6.2,最适离子强度为0.3mol/L。酶反应动力学分析得到结论vMAX=0.064μmol·L-1·min-1,Km=0.265mmol/L。 我们以ALR2和PTP1B为靶点进行天然产物的抑制剂筛选,得到了一味中药地枫皮,它对ALR2和PTP1B都有较好的抑制效果,IC50值分别为59.32μg/mL和60.25μg/mL。通过对抑制类型的检测,我们发现地枫皮提取物对这两种酶的抑制类型均为竞争型。 我们通过超滤质谱技术对地枫皮提取物中的活性成分进行了检测。使用Cl8色谱柱(150mm×4.6mm,5μm),流速为0.5mL/min,进样量为10μL,在254nm为检测波长。洗脱体系由A相(乙腈)和B相(0.5%醋酸水)组成,梯度洗脱:0-20min20%A-20%A;20-35min20%A-38%A;35-50min38%A-45%A;50-55min45%A-60%A;55-65min60%A-75%A;65-70min75%A-85%A;70-80min85%A-100%A;80-90min100%A-100%A对地枫皮提取物进行分离,共有26个色谱峰。 总共从地枫皮提取物中找到了7种化合物与PTP1B和ALR2都有结合作用。我们通过电喷雾离子化线性离子阱质谱对这7种化合物进行结构分析。其中有5种化合物有羰基存在,其余2种化合物中1种为羧酸类物质,还有1种无法判断。我们得出的结论是,带有羰基的C环结构的化合物可能会成为这两个靶点共同的抑制剂,带有2位取代基的呋喃环相邻结构的化合物可能具有更好的抑制活性。
[Abstract]:Diabetes has become the world's top five disease fatality rate. In recent years, the number of patients with DM has increased year by year, and the age of onset has been decreasing. DM and DCC have become serious diseases affecting the quality of life of human beings. However, most of the existing drugs have obvious dose-dependent or unacceptable side effects. Therefore, finding suitable drugs to treat this disease has become the top priority of drug development. In this study, PTP1B and ALR2, the targets of diabetes mellitus and its complications, were studied. Human ALR2 plasmid was constructed using PET-30a vector and expressed in BL21 (DE3) Escherichia coli. A relatively pure human ALR2 protein was obtained by ion exchange and activity tracking. The enzymatic properties showed that when the substrate was DL- glyceraldehyde, the optimum temperature was 37 鈩

本文编号:2420976

资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/nfm/2420976.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户47c21***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com